The National Heart, Lung and Blood Institute Panel on integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents recommended a universal screening approach that would include one-time testing of all children aged 9-11 years for dyslipidemia. This recommendation has raised controversy regarding the identification and treatment of lipid abnormalities in children. Despite these recommendations, universal screening has not become routine: 68% of pediatricians never/rarely/sometimes screened healthy 9- to 11-year-olds.12 One of the reasons against universal screening in children has been the lack of long-term studies evaluating the effectiveness of screening for dyslipidemia in childhood in delaying or reducing the incidence of cardiovascular-related events.
Objectives: The aim of this study was to assess efficacy and tolerability of rosuvastatin in familial hypercholesterolaemic (FH) children aged 6–17 years. Trial registration number: NCT01078675.
E. A. Stein合作论文数2
Brian McCrindle合作论文数The Hospital for Sick Children, Department of Paediatrics, University of Toronto;CHSS Data Center2Raichlen Joel S合作论文数2Braamskamp Marjet J合作论文数2
Daniel Gaudet合作论文数Département de Médecine, Faculté de Médecine,2Claude Gagné合作论文数2Paul D. Martin合作论文数2
Katherine M Morrison合作论文数Department of Pediatrics, McMaster University and Hamilton Health Sciences2Gisle Langslet合作论文数2
Albert Wiegman合作论文数2
David Cassiman合作论文数Department of Hepatology, University Hospital Gasthuisberg2BA Hutten合作论文数1Kusters D Meeike合作论文数1
Kjetil Retterstøl合作论文数Lipid Clin, Oslo Univ Hosp1Evan A. Stein合作论文数1
John Kastelein合作论文数Department of Vascular Medicine, Academic Medical Center, University of Amsterdam;Antoni van Leeuwenhoek Hospital;NewAmsterdam Pharma1Adele Marais合作论文数Faculty of Health Sciences, University of Cape Town1Z. Gu合作论文数1Dirk J. Blom合作论文数Department of Medicine, University of Cape Town1Joseph Ycas合作论文数1Gordon a Francis合作论文数1
